These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 26743094)

  • 21. Scale-up of HIV Viral Load Monitoring--Seven Sub-Saharan African Countries.
    Lecher S; Ellenberger D; Kim AA; Fonjungo PN; Agolory S; Borget MY; Broyles L; Carmona S; Chipungu G; De Cock KM; Deyde V; Downer M; Gupta S; Kaplan JE; Kiyaga C; Knight N; MacLeod W; Makumbi B; Muttai H; Mwangi C; Mwangi JW; Mwasekaga M; Ng'Ang'A LW; Pillay Y; Sarr A; Sawadogo S; Singer D; Stevens W; Toure CA; Nkengasong J
    MMWR Morb Mortal Wkly Rep; 2015 Nov; 64(46):1287-90. PubMed ID: 26605986
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Journey towards universal viral load monitoring in Maputo, Mozambique: many gaps, but encouraging signs.
    Swannet S; Decroo T; de Castro SMTL; Rose C; Giuliani R; Molfino L; Torrens AW; Macueia WSED; Perry S; Reid T
    Int Health; 2017 Jul; 9(4):206-214. PubMed ID: 28810670
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Uptake of routine viral load testing among people living with HIV and its implementation challenges in Yangon region of Myanmar: a mixed-methods study.
    Thinn KK; Thekkur P; Kyaw NTT; Aye NS; Zaw TM; Soan P; Hone S; Oo HN
    BMJ Open; 2019 Dec; 9(12):e032678. PubMed ID: 31796489
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dried blood spot specimens are a suitable alternative sample type for HIV-1 viral load measurement and drug resistance genotyping in patients receiving first-line antiretroviral therapy.
    Rottinghaus EK; Ugbena R; Diallo K; Bassey O; Azeez A; Devos J; Zhang G; Aberle-Grasse J; Nkengasong J; Yang C
    Clin Infect Dis; 2012 Apr; 54(8):1187-95. PubMed ID: 22412066
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Implementation and Operational Research: Programmatic Feasibility of Dried Blood Spots for the Virological Follow-up of Patients on Antiretroviral Treatment in Nord Kivu, Democratic Republic of the Congo.
    Boillot F; Serrano L; Muwonga J; Kabuayi JP; Kambale A; Mutaka F; Fujiwara PI; Decosas J; Peeters M; Delaporte E
    J Acquir Immune Defic Syndr; 2016 Jan; 71(1):e9-15. PubMed ID: 26413848
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A model for reduced HIV-1 viral load monitoring in resource-limited settings.
    Bryant L; Smith N; Keiser P
    J Int Assoc Provid AIDS Care; 2013; 12(1):67-71. PubMed ID: 22553318
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dried blood spots can expand access to virological monitoring of HIV treatment in resource-limited settings.
    Johannessen A; Trøseid M; Calmy A
    J Antimicrob Chemother; 2009 Dec; 64(6):1126-9. PubMed ID: 19776036
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost analysis of centralized viral load testing for antiretroviral therapy monitoring in Nicaragua, a low-HIV prevalence, low-resource setting.
    Gerlach J; Sequeira M; Alvarado V; Cerpas C; Balmaseda A; Gonzalez A; de Los Santos T; Levin CE; Amador JJ; Domingo GJ
    J Int AIDS Soc; 2010 Nov; 13():43. PubMed ID: 21054866
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Beyond first-line HIV treatment regimens: the current state of antiretroviral regimens, viral load monitoring, and resistance testing in resource-limited settings.
    Kumarasamy N; Krishnan S
    Curr Opin HIV AIDS; 2013 Nov; 8(6):586-90. PubMed ID: 24100872
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A simple self-reported adherence tool as a predictor of viral rebound in people with viral suppression on antiretroviral therapy.
    O'Connor JL; Gardner EM; Esser S; Mannheimer SB; Lifson AR; Telzak EE; Phillips AN;
    HIV Med; 2016 Feb; 17(2):124-32. PubMed ID: 26186609
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):e1-89. PubMed ID: 22633764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monitoring of highly active antiretroviral therapy in HIV infection.
    Walker AS; Gibb DM
    Curr Opin Infect Dis; 2011 Feb; 24(1):27-33. PubMed ID: 21150591
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiretroviral treatment failure predicts mortality in rural Tanzania.
    Pettersen PS; Brox IK; Naman E; Bruun JN; Dyrhol-Riise AM; Trøseid M; Johannessen A
    Int J STD AIDS; 2015 Aug; 26(9):633-9. PubMed ID: 25122578
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of point-of-care viral load monitoring in achieving the target of 90% suppression in HIV-infected patients in Nigeria: study protocol for a randomized controlled trial.
    Meloni ST; Agbaji O; Chang CA; Agaba P; Imade G; Oguche S; Mukhtar A; Mitruka K; Cox MH; Zee A; Kanki P
    BMC Infect Dis; 2019 May; 19(1):368. PubMed ID: 31046695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV-1 viral load testing in resource-limited settings: Challenges and solutions for specimen integrity.
    Newman H; Hardie D
    Rev Med Virol; 2021 Mar; 31(2):e2165. PubMed ID: 32978882
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of treatment outcomes for patients on first-line regimens in US President's Emergency Plan for AIDS Relief (PEPFAR) clinics in Uganda: predictors of virological and immunological response from RV288 analyses.
    Crawford KW; Wakabi S; Magala F; Kibuuka H; Liu M; Hamm TE
    HIV Med; 2015 Feb; 16(2):95-104. PubMed ID: 25124078
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.
    Soria A; Porten K; Fampou-Toundji JC; Galli L; Mougnutou R; Buard V; Kfutwah A; Vessière A; Rousset D; Teck R; Calmy A; Ciaffi L; Lazzarin A; Gianotti N
    Antivir Ther; 2009; 14(3):339-47. PubMed ID: 19474468
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dried blood spots in HIV monitoring: applications in resource-limited settings.
    Johannessen A
    Bioanalysis; 2010 Nov; 2(11):1893-908. PubMed ID: 21083497
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Challenges and opportunities for the implementation of virological testing in resource-limited settings.
    Roberts T; Bygrave H; Fajardo E; Ford N
    J Int AIDS Soc; 2012 Oct; 15(2):17324. PubMed ID: 23078767
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.